30 Jan 2023 , 10:12 AM
Result date: 31st January, 2023
Recommendation: Buy
Target price: Rs1,170
Continued momentum in Specialty business (Winlevi, Illmya and Cequa) could aid December 2022 quarter performance of Sun Pharmaceutical Industries (Sun Pharma). The US generics business (excluding Taro) could perform well amid new launches and robust volumes in key products. Taro, on the other hand, could remain weak owing to high competitive intensity, price erosion and absence of significant launches. Revenue of domestic business could grow in low-single digits, on the back of all-round growth across segments. Consequently, revenue growth is estimated at 13% as compared to the year-ago quarter.
Sun Pharma is expected to maintain EBITDA margin at 26% levels despite higher spends towards R&D.
Profit After Tax or PAT of the company could grow 7% over the year-ago quarter.
Important management insights to watch out for:
December 2022 estimates |
YoY change |
QoQ change |
|
Revenue (Rs mn) |
110,520 |
13% |
2% |
EBITDA (Rs mn) |
29,288 |
14% |
(4)% |
EBITDA margin |
26.2% |
33 bps |
(176) bps |
Profit After Tax (Rs mn) |
22,004 |
7% |
(3)% |
Source: IIFL Research
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.